Johnson & Johnson price target raised to $240 from $227 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $240 from $227 and keeps a Buy rating on the shares after the company reported “solid” Q4 results and provided initial 2026 guidance that was slightly ahead of sell-side estimates. Following the quarter, the firm is making several adjustments to its model, including raising near-term Tremfya estimates, accelerating Stelara erosion, and raising estimates for multiple newer products, says the analyst, who continues to identify J&J as a Top Picks in the large cap biopharma sector.